Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1983 4
1984 4
1985 7
1986 8
1987 9
1988 5
1989 10
1990 14
1991 16
1992 22
1993 19
1994 25
1995 32
1996 36
1997 31
1998 29
1999 36
2000 34
2001 39
2002 51
2003 47
2004 50
2005 56
2006 61
2007 66
2008 78
2009 84
2010 79
2011 102
2012 109
2013 112
2014 122
2015 131
2016 130
2017 149
2018 165
2019 169
2020 152
2021 177
2022 162
2023 127
2024 68

Text availability

Article attribute

Article type

Publication date

Search Results

2,542 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "ALG3-congenital disorder of glycosylation"
Page 1
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies.
Mueller AL, Payandeh Z, Mohammadkhani N, Mubarak SMH, Zakeri A, Alagheband Bahrami A, Brockmueller A, Shakibaei M. Mueller AL, et al. Cells. 2021 Nov 4;10(11):3017. doi: 10.3390/cells10113017. Cells. 2021. PMID: 34831240 Free PMC article. Review.
Rheumatoid arthritis (RA) is considered a chronic systemic, multi-factorial, inflammatory, and progressive autoimmune disease affecting many people worldwide. While patients show very individual courses of disease, with RA focusing on the musculoskeletal syst …
Rheumatoid arthritis (RA) is considered a chronic systemic, multi-factorial, inflammatory, and progressive autoimmune disease affecti …
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Luo G, et al. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409. doi: 10.1016/j.bbcan.2020.188409. Epub 2020 Aug 19. Biochim Biophys Acta Rev Cancer. 2021. PMID: 32827580 Review.
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker, predictor, and promoter in pancreatic cancer. ...CA19-9 has screening potential when combined with sy …
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. C …
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, Sanin DE, Jacob F, Coelho R, Everest-Dass AV, Wang J, Trefny MP, Monaco G, Bärenwaldt A, Gray MA, Petrone A, Kashyap AS, Glatz K, Kasenda B, Normington K, Broderick J, Peng L, Pearce OMT, Pearce EL, Bertozzi CR, Zippelius A, Läubli H. Stanczak MA, et al. Sci Transl Med. 2022 Nov 2;14(669):eabj1270. doi: 10.1126/scitranslmed.abj1270. Epub 2022 Nov 2. Sci Transl Med. 2022. PMID: 36322632 Free PMC article.
Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with cancer, but the majority experiences limited benefit, supporting the need for new therapeutic approaches. Up-regulation of sialic acid-containing glycans, termed hypersialylation, is …
Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with cancer, but the majority experiences limit …
MUC1: An emerging target in cancer treatment and diagnosis.
Qing L, Li Q, Dong Z. Qing L, et al. Bull Cancer. 2022 Nov;109(11):1202-1216. doi: 10.1016/j.bulcan.2022.08.001. Epub 2022 Sep 30. Bull Cancer. 2022. PMID: 36184332 Review.
MUC1 is a highly glycosylated transmembrane mucin on the luminal surface of epithelial cells, protecting them from extreme factors. ...MUC1 glycosylation insufficiency leads to exposure of novel antigenic epitopes that can be used as specific targets for therapy and …
MUC1 is a highly glycosylated transmembrane mucin on the luminal surface of epithelial cells, protecting them from extreme factors. . …
International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.
Altassan R, Péanne R, Jaeken J, Barone R, Bidet M, Borgel D, Brasil S, Cassiman D, Cechova A, Coman D, Corral J, Correia J, de la Morena-Barrio ME, de Lonlay P, Dos Reis V, Ferreira CR, Fiumara A, Francisco R, Freeze H, Funke S, Gardeitchik T, Gert M, Girad M, Giros M, Grünewald S, Hernández-Caselles T, Honzik T, Hutter M, Krasnewich D, Lam C, Lee J, Lefeber D, Marques-de-Silva D, Martinez AF, Moravej H, Õunap K, Pascoal C, Pascreau T, Patterson M, Quelhas D, Raymond K, Sarkhail P, Schiff M, Seroczyńska M, Serrano M, Seta N, Sykut-Cegielska J, Thiel C, Tort F, Vals MA, Videira P, Witters P, Zeevaert R, Morava E. Altassan R, et al. J Inherit Metab Dis. 2019 Jan;42(1):5-28. doi: 10.1002/jimd.12024. J Inherit Metab Dis. 2019. PMID: 30740725
Phosphomannomutase 2 (PMM2-CDG) is the most common congenital disorder of N-glycosylation and is caused by a deficient PMM2 activity. ...
Phosphomannomutase 2 (PMM2-CDG) is the most common congenital disorder of N-glycosylation and is caused by a deficient PMM2 ac …
Glycosylation and Cardiovascular Diseases.
Dashti H, Pabon Porras MA, Mora S. Dashti H, et al. Adv Exp Med Biol. 2021;1325:307-319. doi: 10.1007/978-3-030-70115-4_15. Adv Exp Med Biol. 2021. PMID: 34495542
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for approximately 18 million deaths in 2017. Coronary artery disease is the predominant cause of death from CVD, followed by stroke. ...
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for approximately 18 million deaths in 2017. Coronar …
Gain-of-glycosylation mutations.
Vogt G, Vogt B, Chuzhanova N, Julenius K, Cooper DN, Casanova JL. Vogt G, et al. Curr Opin Genet Dev. 2007 Jun;17(3):245-51. doi: 10.1016/j.gde.2007.04.008. Epub 2007 Apr 30. Curr Opin Genet Dev. 2007. PMID: 17467977 Review.
A pathogenic mechanism involves the addition of a novel N-linked glycan. Up to 1.4% of known disease-causing missense mutations are predicted to give rise to gains-of-glycosylation. ...The chemical complementation of cells from patients in vitro with various …
A pathogenic mechanism involves the addition of a novel N-linked glycan. Up to 1.4% of known disease-causing missense mutations are …
Altered glycosylation in pancreatic cancer and beyond.
Lumibao JC, Tremblay JR, Hsu J, Engle DD. Lumibao JC, et al. J Exp Med. 2022 Jun 6;219(6):e20211505. doi: 10.1084/jem.20211505. Epub 2022 May 6. J Exp Med. 2022. PMID: 35522218 Free PMC article. Review.
Median survival of PDA patients is 6-10 mo, with the majority of diagnoses occurring at later, metastatic stages that are refractory to treatment and accompanied by worsening prognoses. Glycosylation is one of the most common types of post-translational modification …
Median survival of PDA patients is 6-10 mo, with the majority of diagnoses occurring at later, metastatic stages that are refractory to trea …
Congenital disorders of glycosylation (CDG): Quo vadis?
Péanne R, de Lonlay P, Foulquier F, Kornak U, Lefeber DJ, Morava E, Pérez B, Seta N, Thiel C, Van Schaftingen E, Matthijs G, Jaeken J. Péanne R, et al. Eur J Med Genet. 2018 Nov;61(11):643-663. doi: 10.1016/j.ejmg.2017.10.012. Epub 2017 Oct 25. Eur J Med Genet. 2018. PMID: 29079546 Free article. Review.
The survey summarizes in its first part the current status of knowledge on the Congenital Disorders of Glycosylation (CDG) with regard to their phenotypic spectrum, diagnostic and therapeutic strategies, and pathophysiology. ...Networking (EURO-CDG, the European Ref …
The survey summarizes in its first part the current status of knowledge on the Congenital Disorders of Glycosylation (CDG) wit …
Mucin-Type O-Glycosylation in Gastric Carcinogenesis.
Duarte HO, Freitas D, Gomes C, Gomes J, Magalhães A, Reis CA. Duarte HO, et al. Biomolecules. 2016 Jul 11;6(3):33. doi: 10.3390/biom6030033. Biomolecules. 2016. PMID: 27409642 Free PMC article. Review.
Modifications in enzymes responsible for key glycosylation steps and the consequent abnormal biosynthesis and expression of their glycan products constitute well-established molecular hallmarks of disease state. ...Furthermore, alterations of mucin expression patter …
Modifications in enzymes responsible for key glycosylation steps and the consequent abnormal biosynthesis and expression of their gly …
2,542 results